Literature DB >> 11518272

Quadriceps protects the anterior cruciate ligament.

M Bodor1.   

Abstract

The aim of this study is to show that the quadriceps is the primary muscular restraint to anterior tibial translation during closed kinetic chain activities such as running, jumping, walking, and standing. It is my hypothesis that the quadriceps vector is directed superiorly during open kinetic chain knee extension and inferiorly during closed kinetic chain knee extension. My methods involve vector analysis based on a lateral radiograph of the normal human knee and muscle ultrasound. My results show that the quadriceps vector is directed superiorly for open kinetic chain knee extension and inferiorly for closed kinetic chain knee extension. The inferiorly directed quadriceps vector has an anterior femoral-tibial or posterior tibial-femoral component, which protects the anterior cruciate ligament (ACL) from anterior tibial-femoral shear. Therefore during closed kinetic chain activities, the quadriceps protects the ACL regardless of the activity of the hamstrings. Given that the quadriceps is much stronger than the hamstrings, has better leverage at low knee flexion angles, and a favorable vector with regard to the ACL during closed kinetic chain activities, and since most activities of daily living, sports, and non-contact ACL injuries occur with the foot on the ground, then it can be concluded that the quadriceps is the primary ACL protagonist. My findings have the following implications: (1) weak quadriceps are a risk factor for non-contact ACL injuries, (2) strong quadriceps are important for ACL injury prevention and rehabilitation, and (3) preservation of quadriceps strength is an important surgical goal.

Entities:  

Mesh:

Year:  2001        PMID: 11518272     DOI: 10.1016/S0736-0266(01)00050-X

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  8 in total

1.  The vector of quadriceps pull is directed from the patella to the femoral neck.

Authors:  Osamu Tanifuji; John David Blaha; Shin Kai
Journal:  Clin Orthop Relat Res       Date:  2012-12-20       Impact factor: 4.176

Review 2.  Neuromuscular interactions around the knee in children, adults and elderly.

Authors:  Eleftherios Kellis; Lida Mademli; Dimitrios Patikas; Nikolaos Kofotolis
Journal:  World J Orthop       Date:  2014-09-18

3.  Early versus late start of open kinetic chain quadriceps exercises after ACL reconstruction with patellar tendon or hamstring grafts: a prospective randomized outcome study.

Authors:  Annette Heijne; Suzanne Werner
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2007-01-12       Impact factor: 4.342

4.  Study on three-dimensional kinematics and electromyography of ACL deficient knee participants wearing a functional knee brace during running.

Authors:  Daniel Théoret; Mario Lamontagne
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2006-04-06       Impact factor: 4.342

5.  Avulsion Fracture of Bicruciate Ligament and Patellar Tendon in Bicruciate-Retaining Total Knee Arthroplasty.

Authors:  Lawrence Chun-Man Lau; Michael Tim-Yun Ong; Wai-Wang Chau; Jonathan Patrick Ng; James F Griffith; Kevin Ki-Wai Ho
Journal:  Arthroplast Today       Date:  2022-05-27

6.  Hamstring weakness as an indicator of poor knee function in ACL-deficient patients.

Authors:  E Tsepis; G Vagenas; G Giakas; A Georgoulis
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2003-09-11       Impact factor: 4.342

7.  Repeatability and accuracy of a non-invasive method of measuring internal and external rotation of the tibia.

Authors:  David F Russell; Angela H Deakin; Quentin A Fogg; Frederic Picard
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2013-12-27       Impact factor: 4.342

8.  Efficacy of non-surgical management and functional outcomes of partial ACL tears. A systematic review of randomised trials.

Authors:  Michael Giummarra; Loretta Vocale; Matthew King
Journal:  BMC Musculoskelet Disord       Date:  2022-04-08       Impact factor: 2.362

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.